Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination

Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are being made. By using a different and better sulphonamide (sulphamethoxypyrazine...

Descripción completa

Detalles Bibliográficos
Autor principal: Jansen, Frans Herwig
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078902/
https://www.ncbi.nlm.nih.gov/pubmed/21443809
http://dx.doi.org/10.1186/1475-2875-10-70
_version_ 1782201986270101504
author Jansen, Frans Herwig
author_facet Jansen, Frans Herwig
author_sort Jansen, Frans Herwig
collection PubMed
description Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are being made. By using a different and better sulphonamide (sulphamethoxypyrazine), it is possible to manufacture fixed dose combination pills with artesunate and pyrimethamine. This combination permits a full therapy over 24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field studies of IPTi.
format Text
id pubmed-3078902
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30789022011-04-19 Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination Jansen, Frans Herwig Malar J Commentary Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are being made. By using a different and better sulphonamide (sulphamethoxypyrazine), it is possible to manufacture fixed dose combination pills with artesunate and pyrimethamine. This combination permits a full therapy over 24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field studies of IPTi. BioMed Central 2011-03-29 /pmc/articles/PMC3078902/ /pubmed/21443809 http://dx.doi.org/10.1186/1475-2875-10-70 Text en Copyright ©2011 Jansen; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Jansen, Frans Herwig
Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
title Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
title_full Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
title_fullStr Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
title_full_unstemmed Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
title_short Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
title_sort intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078902/
https://www.ncbi.nlm.nih.gov/pubmed/21443809
http://dx.doi.org/10.1186/1475-2875-10-70
work_keys_str_mv AT jansenfransherwig intermittentpreventivetherapyformalariaargumentsinfavourofartesunateandsulphamethoxypyrazinepyrimethaminecombination

Ejemplares similares